イノベーションと知的財産 · 1996/5/221 分で読めます
Notice of Two Year Exclusivity Period; DAYPRORegister Oxaprozin
ローカル自動翻訳 · 情報源の原言語
概要
The Patent and Trademark Office has received notification from G. D. Searle & Co. that it claims entitlement under section 2105 of the FDA Export Reform and Enhancement Act of 1996 (Chapter 1A of Pub. L. No. 104-134) for its drug product DAYPRO oxaprozin.